UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid a...Show More
peer of
competitor of
Metrics
marketSTOCKS
msh_idCOM:UCB
localebe
websitehttps://www.ucb.com/
ipo_date2000-01-04
primary_stock_msh_idEURONEXT:UCB
source_ref25183f59-f711-49d5-9ea1-e211714ad030
products_or_servicesUCB offers pharmaceutical products, including therapies for epilepsy, autoimmune diseases, and other neurological disorders.